HIV-related CD8+ cutaneous pseudolymphoma: efficacy of methotrexate.

Abstract

Human immunodeficiency virus (HIV)-related CD8+ cutaneous pseudolymphoma (CD8+ cytotoxic T cell skin infiltrative disease) is an inflammatory process resulting from a massive infiltration of the skin by activated, oligoclonal, HIV-specific, cytotoxic T lymphocytes. Usually, CD8+ cutaneous pseudolymphoma affects patients with a deep immunosuppression, and is rare in patients with mild immunosuppression. In deeply immunocompromised patients, highly active antiretroviral therapy (HAART) is considered as the first-line treatment. In contrast, the choice of therapy in moderately immunocompromised patients and/or patients already receiving HAART remains nonconsensual. We report a case of HIV-related CD8+ cutaneous pseudolymphoma in a moderately immunocompromised patient who was successfully and safely treated with methotrexate. We review the literature on HIV-related CD8+ pseudolymphoma and the use of methotrexate in HIV-positive patients.

• Authors: S Ingen-Housz-Oro, E Sbidian, N Ortonne, D Penso-Assathiany, V Chambrin, M Bagot, H Bachelez, P Wolkenstein, O Chosidow
• Journal: Dermatology (Basel, Switzerland) (Dermatology) Vol. 226 Issue 1 Pg. 15-8 ( 2013) ISSN: 1421-9832 [Electronic] Switzerland
• PMID: 23343593 (Publication Type: Case Reports, Journal Article, Review)
• Copyright: Copyright © 2013 S. Karger AG, Basel.

Chemical References

• Dermatologic Agents
• Methotrexate

Topics

• Antiretroviral Therapy, Highly Active (methods)
• CD8-Positive T-Lymphocytes (drug effects)
• Dermatologic Agents (therapeutic use)
• HIV Infections (drug therapy, immunology)
• Humans
• Immunocompromised Host
• Male
• Methotrexate (therapeutic use)
• Middle Aged
• Pseudolymphoma (drug therapy, immunology)
• Skin Diseases (drug therapy, immunology)
• Treatment Outcome